Medical Doctor Program year 2024 Reported 2023–2024 Source: CMS Open Payments, 2026 publication

Charles Ripp

Pain Medicine Colorado Springs, CO Medical Doctor

NPI 1013916881 CMS profile 562720

8540 Scarborough Dr, Suite 370, Colorado Springs, CO 80920

Open in the dashboard

General payments

$229

4 records reported · program years 2023–2024

Research payments

$0

Paid to them · None reported · program years 2023–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Charles Ripp of Colorado Springs, CO is reported in the CMS Open Payments database as having received $229 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 19th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $25 1
2023 General $204 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Ripp
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Charles Ripp were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Charles Ripp Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $0 $455 $137–$1,484 $149
2023 $204 $484 $128–$1,495 $160
2024 $25 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2023–2024
  1. Relievant Medsystems, Inc. $96 1 payment
  2. SPR Therapeutics, Inc $55 1 payment
  3. Medtronic, Inc. $53 1 payment
  4. Hologic, LLC $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2024
  1. Food and Beverage $176 3 payments
  2. Grant $53 1 payment
Products named General payments · program years 2023–2024
  1. Intracept Pain $96 1 payment
  2. Intracept Pain $96 1 payment
  3. Intracept Pain $96 1 payment
  4. Intracept Pain $96 1 payment
  5. SPRINT PNS System $55 1 payment
  6. SYNCHROMEDII $53 1 payment
  7. THINPREP 2000 PROCESSOR $25 1 payment
  8. Aptima $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

785

Median for Pain Management: 951

Drug cost

$67,236

Median for Pain Management: $26,034

Branded share of claims

17.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fentanyl Citrate Generic 11 $27,289
Xtampza Er Oxycodone Myristate Brand 14 $25,254
Fentanyl Generic 30 $3,605
Oxycodone Hcl Generic 95 $2,465
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 67 $2,013
Tramadol Hcl Generic 64 $1,156
Gabapentin Generic 64 $990
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 16 $764
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $716
Methocarbamol Generic 34 $551

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$121,030

Of which drugs: $1,690

Medicare patients

118

Average age 69

Services billed

13,668

73 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 65%
Depression 41%
Diabetes 26%
COPD 25%
Ischemic heart disease 20%
Chronic kidney disease 19%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 38 12,572 $1,334

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record